COVESTRO AG (1COV.DE) Stock Fundamental Analysis
Europe - FRA:1COV - DE0006062144 - Common Stock
59.62 EUR
-0.56 (-0.93%)
1COV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 69 industry peers in the Chemicals industry. 1COV may be in some trouble as it scores bad on both profitability and health. 1COV has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year 1COV has reported negative net income.
In the past year 1COV had a positive cash flow from operations.
In multiple years 1COV reported negative net income over the last 5 years.
Each year in the past 5 years 1COV had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -3.46%, 1COV is doing worse than 73.91% of the companies in the same industry.
1COV has a Return On Equity of -7.52%. This is in the lower half of the industry: 1COV underperforms 75.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.46% | ||
| ROE | -7.52% | ||
| ROIC | N/A |
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
1COV's Operating Margin has declined in the last couple of years.
1COV has a worse Gross Margin (13.93%) than 75.36% of its industry peers.
1COV's Gross Margin has declined in the last couple of years.
1COV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.93% |
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
2. Health
2.1 Basic Checks
1COV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1COV remains at a similar level compared to 1 year ago.
The number of shares outstanding for 1COV has been increased compared to 5 years ago.
Compared to 1 year ago, 1COV has an improved debt to assets ratio.
2.2 Solvency
1COV has an Altman-Z score of 2.28. This is not the best score and indicates that 1COV is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.28, 1COV is in line with its industry, outperforming 50.72% of the companies in the same industry.
1COV has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
1COV has a Debt to Equity ratio (0.34) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.28 |
ROIC/WACCN/A
WACC6.39%
2.3 Liquidity
A Current Ratio of 1.36 indicates that 1COV should not have too much problems paying its short term obligations.
1COV has a Current ratio of 1.36. This is in the lower half of the industry: 1COV underperforms 76.81% of its industry peers.
1COV has a Quick Ratio of 1.36. This is a bad value and indicates that 1COV is not financially healthy enough and could expect problems in meeting its short term obligations.
1COV's Quick ratio of 0.73 is on the low side compared to the rest of the industry. 1COV is outperformed by 76.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
The earnings per share for 1COV have decreased strongly by -76.09% in the last year.
The Revenue has decreased by -5.27% in the past year.
Measured over the past years, 1COV shows a small growth in Revenue. The Revenue has been growing by 2.70% on average per year.
EPS 1Y (TTM)-76.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-247.06%
Revenue 1Y (TTM)-5.27%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-11.99%
3.2 Future
Based on estimates for the next years, 1COV will show a very strong growth in Earnings Per Share. The EPS will grow by 20.37% on average per year.
The Revenue is expected to grow by 1.10% on average over the next years.
EPS Next Y-32.24%
EPS Next 2Y58.67%
EPS Next 3Y43.92%
EPS Next 5Y20.37%
Revenue Next Year-7.47%
Revenue Next 2Y-2.57%
Revenue Next 3Y-0.46%
Revenue Next 5Y1.1%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for 1COV. In the last year negative earnings were reported.
1COV is valuated quite expensively with a Price/Forward Earnings ratio of 81.09.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1COV indicates a slightly more expensive valuation: 1COV is more expensive than 69.57% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.62. 1COV is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 81.09 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1COV indicates a slightly more expensive valuation: 1COV is more expensive than 68.12% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 17.04 |
4.3 Compensation for Growth
1COV's earnings are expected to grow with 43.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.67%
EPS Next 3Y43.92%
5. Dividend
5.1 Amount
No dividends for 1COV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:1COV (11/17/2025, 7:00:00 PM)
59.62
-0.56 (-0.93%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners25.07%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap11.27B
Revenue(TTM)13.40B
Net Income(TTM)-458.00M
Analysts49.47
Price Target61.85 (3.74%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.01
Dividend Growth(5Y)-70.61%
DP-0.22%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-69.67%
Min EPS beat(2)-139.31%
Max EPS beat(2)-0.04%
EPS beat(4)0
Avg EPS beat(4)-380.46%
Min EPS beat(4)-1222.75%
Max EPS beat(4)-0.04%
EPS beat(8)1
Avg EPS beat(8)-4244%
EPS beat(12)2
Avg EPS beat(12)-2876.36%
EPS beat(16)3
Avg EPS beat(16)-2162.14%
Revenue beat(2)0
Avg Revenue beat(2)-4.63%
Min Revenue beat(2)-6.91%
Max Revenue beat(2)-2.34%
Revenue beat(4)0
Avg Revenue beat(4)-4.71%
Min Revenue beat(4)-6.91%
Max Revenue beat(4)-2.34%
Revenue beat(8)0
Avg Revenue beat(8)-4.43%
Revenue beat(12)0
Avg Revenue beat(12)-4.49%
Revenue beat(16)3
Avg Revenue beat(16)-2.5%
PT rev (1m)-0.2%
PT rev (3m)-2.05%
EPS NQ rev (1m)0.92%
EPS NQ rev (3m)-62.85%
EPS NY rev (1m)-23.58%
EPS NY rev (3m)-689.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.17%
Revenue NY rev (1m)-0.56%
Revenue NY rev (3m)-7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 81.09 | ||
| P/S | 0.84 | ||
| P/FCF | N/A | ||
| P/OCF | 14.12 | ||
| P/B | 1.85 | ||
| P/tB | 2.27 | ||
| EV/EBITDA | 17.04 |
EPS(TTM)-2.43
EYN/A
EPS(NY)0.74
Fwd EY1.23%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)4.22
OCFY7.08%
SpS70.92
BVpS32.22
TBVpS26.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.46% | ||
| ROE | -7.52% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.93% | ||
| FCFM | N/A |
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)6.03%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
F-Score3
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.47 | ||
| Cap/Depr | 92.05% | ||
| Cap/Sales | 6.83% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 95% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 2.28 |
F-Score3
WACC6.39%
ROIC/WACCN/A
Cap/Depr(3y)75.52%
Cap/Depr(5y)82.02%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-247.06%
EPS Next Y-32.24%
EPS Next 2Y58.67%
EPS Next 3Y43.92%
EPS Next 5Y20.37%
Revenue 1Y (TTM)-5.27%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-11.99%
Revenue Next Year-7.47%
Revenue Next 2Y-2.57%
Revenue Next 3Y-0.46%
Revenue Next 5Y1.1%
EBIT growth 1Y-220.31%
EBIT growth 3Y-79.32%
EBIT growth 5Y-52.83%
EBIT Next Year267.68%
EBIT Next 3Y84.36%
EBIT Next 5Y42.34%
FCF growth 1Y-116.5%
FCF growth 3Y-60.36%
FCF growth 5Y-28.37%
OCF growth 1Y-45.3%
OCF growth 3Y-26.52%
OCF growth 5Y-8.84%
COVESTRO AG / 1COV.DE FAQ
What is the fundamental rating for 1COV stock?
ChartMill assigns a fundamental rating of 2 / 10 to 1COV.DE.
What is the valuation status of COVESTRO AG (1COV.DE) stock?
ChartMill assigns a valuation rating of 1 / 10 to COVESTRO AG (1COV.DE). This can be considered as Overvalued.
Can you provide the profitability details for COVESTRO AG?
COVESTRO AG (1COV.DE) has a profitability rating of 1 / 10.
How financially healthy is COVESTRO AG?
The financial health rating of COVESTRO AG (1COV.DE) is 3 / 10.